Shanghai New Asia Pioneer Pharmaceuticals CO., LTD was set up on the basis of the former Shanghai Pioneer Pharmaceuticals CO., Shanghai New Asia Pharmaceuticals CO., as well as Shanghai NO. 4 Pharmaceuticals CO. through transformation from debt to shares, reorganization of capitals. Chambers Yang has offered high-quality legal service for such transaction and was retained as the legal advisor for it.
相关法律服务
杨春宝一级律师简介
杨春宝一级律师，大成上海高级合伙人、资本市场部主任、国资基金研究中心主任，大成中国区私募基金专业带头人、科技与文化法律研究中心联合牵头人。执业30余年，长期从事私募基金、投融资、并购重组法律服务，尤其对对赌研究颇深且具有非常丰富的实战经验，并专注于金融机构股权投资业务。2004年起多次入选The Legal 500"私募基金"和"公司与商业"等境内外各类律师榜单，代理的中国法院首例适用外国法律审理外国公司的董事损害小股东权益纠纷案入选上海高院发布的《上海法院域外法查明典型案例》和威科先行"要案头条"。入选上海涉外法律人才库、上海市司法局鼎新法治人才库、上海国有企业改制法律顾问团，具有上市公司独立董事任职资格，系多家知名高校的兼职教授或兼职研究生导师及上海市商务委跨国经营人才培训班讲师。出版《私募股权投资基金风险防控操作实务》等16本投融资法律专著。了解更多常见法律问题
What legal issues arise in the debt-to-share transformation and capital reorganization of pharmaceutical companies in China?
Debt-to-share transformation and capital reorganization of pharmaceutical companies in China involve complex legal issues: (1) valuation of debt and equity must comply with the Asset Appraisal Law and relevant regulations, requiring independent third-party appraisal; (2) creditor approval is required under the Company Law, as debt-to-equity swaps constitute a fundamental change in creditor rights; (3) pharmaceutical license transfers, including the Drug Manufacturing Certificate and Drug Registration Certificates, are subject to National Medical Products Administration (NMPA) approval and cannot be transferred freely; (4) employee shareholding arrangements must comply with the Labor Contract Law and social insurance obligations; and (5) regulatory filings with the State Administration for Market Regulation (SAMR) for anti-monopoly review may be required if the reorganization meets certain thresholds.
What are the key legal compliance requirements for establishing a pharmaceutical company through corporate restructuring in Shanghai?
Establishing a pharmaceutical company through restructuring in Shanghai requires compliance with: (1) the Drug Administration Law and its implementing regulations, including GMP (Good Manufacturing Practice) certification for production facilities; (2) the Company Law for merger or division procedures, including creditor notification and public announcement requirements; (3) the Shanghai Free Trade Zone regulations if the entity is established within the FTZ, which may offer simplified procedures for foreign investment; (4) the Pharmaceutical Management Law for drug distribution and wholesale licensing; (5) environmental protection laws requiring Environmental Impact Assessment (EIA) for pharmaceutical production facilities; and (6) ongoing compliance with the NMPA’s pharmacovigilance obligations for post-market drug safety monitoring.
What legal considerations apply when multiple pharmaceutical companies merge through capital reorganization?
When multiple pharmaceutical companies merge through capital reorganization, the following legal considerations apply: (1) the merger plan must be approved by the shareholders’ meeting of each participating company with a supermajority vote (two-thirds or more); (2) the surviving entity must assume all debts and liabilities of the merged entities, and creditors have the right to demand repayment or security within the statutory objection period; (3) all pharmaceutical licenses and permits held by the merging entities must be reassessed and re-registered under the surviving entity’s name with NMPA approval; (4) intellectual property assets, including drug patents, trademarks, and trade secrets, require proper assignment agreements and registration with the China National Intellectual Property Administration (CNIPA); and (5) labor contracts must be handled in accordance with the Labor Contract Law, with employees of the merging entities continuing their employment under the surviving entity.
以上内容仅供参考，不构成法律意见。如需专业法律服务，请联系杨春宝一级律师：chambers.yang@dentons.cn
